Premium
Fluconazole vs. Itraconazole in the treatment of tinea versicolor
Author(s) -
MonteroGei Fernando,
Robles Miguel Eduardo,
Suchil Patricia
Publication year - 1999
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1046/j.1365-4362.1999.00733.x
Subject(s) - fluconazole , itraconazole , medicine , adverse effect , mycosis , antifungal , cure rate , pharmacology , gastroenterology , dermatology , surgery
Ninety patients with tinea versicolor were randomly assigned to treatment with either a single 450‐mg dose of fluconazole, two 300‐mg doses of fluconazole given 1 week apart, or itraconazole 200 mg daily for 7 days. At the end of treatment, the cure rate for itraconazole (20%) was significantly higher ( P = 0.024) than that for fluconazole 450 mg (0%). When cure plus improvement was considered, response rates among the three treatment groups were comparable (97, 100, and 97% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively). Failure rates at the end of treatment were low (0–3%). Clinical response rates achieved at the end of treatment generally were maintained at 1 month, but tended to decrease at 2 months. Eradication at the end of treatment was not significantly different among the treatment groups (17, 33, and 38% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively). At 1 month, the eradication rate was significantly higher ( P = 0.012) for the two‐dose than the single‐dose fluconazole treatment group (97 and 70%, respectively). At 2 months, reinfection rates were 21, 20, and 4% for fluconazole 450 mg, fluconazole 300 mg, and itraconazole, respectively. No clinical adverse events occured, and no patients were withdrawn for laboratory abnormalities.